-
Cyclic di-GMP for Biofilm and STING Research
2026-08-20
Cyclic di-GMP connects bacterial biofilm persistence research with STING-focused immune modulation research. This practical guide explains how to handle the water-soluble messenger, design stage-aware bacterial assays, and interpret exploratory applications in cancer immunotherapy studies.
-
Deferasirox: Pharmacokinetics and Clinical Evidence
2026-08-20
Galanello, Campus, and Origa synthesized pharmacokinetic, pharmacodynamic, efficacy, and safety evidence for deferasirox across transfusion-dependent anemias. Their review framed Exjade as an oral alternative to infusion-based chelation while emphasizing individualized dosing, laboratory monitoring, and the persistent problem of incomplete response.
-
Phosbind Biotin LC: PVDF Phosphoprotein Detection
2026-08-19
Phosbind Biotin LC is a phosphate-binding reagent for detecting phosphorylated proteins on PVDF membranes without relying on phospho-specific antibody sequence recognition. It is intended for Western Blot workflows with streptavidin-HRP and chemiluminescence, not aqueous-only protocols, water-based preparation, or long-term storage of working solutions.
-
Difloxacin HCl: Assay Workflows and Optimization
2026-08-19
Difloxacin HCl supports two distinct research workflows: bacterial DNA gyrase inhibition measured by antimicrobial susceptibility testing and exploratory multidrug resistance reversal studies based on MRP substrate sensitization. This guide connects formulation, assay design, checkpoint-biology context, and troubleshooting without treating research observations as clinical breakpoints.
-
Ferrostatin-1: Ferroptosis Assay Workflow
2026-08-18
Ferrostatin-1 (Fer-1) provides a practical rescue control for distinguishing lipid-peroxidation-driven cell death from nonspecific toxicity. This guide translates trophoblast ferroptosis findings into reproducible workflows for cancer biology research, neurodegenerative disease models, and oxidative injury studies.
-
LC–MS/MS Mapping of NGP-1 Conversion Pathways
2026-08-18
A January 2026 Microchemical Journal study established an LC–MS/MS workflow to track conversion of the GS-441524 prodrug NGP-1 across gastric, blood, hepatic, and in vivo rat systems. The results indicate that NGP-1 can generate GS441 at multiple sites, providing a mechanistic framework for interpreting oral exposure and GS-441524 pharmacokinetics.
-
Wortmannin for PI3K/AKT Ferroptosis Studies
2026-08-17
Use Wortmannin as a mechanistic PI3K inhibitor to connect FAT4 loss, AKT activation, and ferroptosis resistance in hepatocellular carcinoma models. This guide combines pathway-focused workflows, assay controls, solubility guidance, and troubleshooting for cancer research applications.
-
ONX-0914: From LMP7 Selectivity to Assay Design
2026-08-17
ONX-0914 (PR-957) is a selective LMP7 inhibitor whose value extends beyond cytokine suppression. This article explains how target selectivity, exposure history, and stimulation paradigm can be integrated to improve autoimmune, inflammatory, and neurobiology assay design.
-
BAPTA-AM: Cell-Permeable Calcium Chelator
2026-08-16
BAPTA-AM enables controlled intracellular Ca²⁺ depletion for calcium signaling, apoptosis, and neuronal injury experiments. Its rapid cell entry is useful for mechanistic rescue studies, but potassium-channel activity and magnesium interference require carefully matched controls.
-
Deferasirox Fe3+ Chelate in Lysosomal Iron Research
2026-08-15
Deferasirox Fe3+ chelate offers a precise way to study ferric-iron handling alongside nutrient-stress biology. This article connects Exjade-related iron chelation research with TCF25-driven lysosomal acidification and ferritinophagy, while defining controls that prevent misinterpreting a preformed chelate as free ligand.
-
Natural-Product Screening of SARS-CoV-2 NSP15
2026-08-14
A 2021 structure-based study screened a natural-product library against the SARS-CoV-2 NSP15 endoribonuclease and identified thymopentin and oleuropein as the leading computational hits. Molecular-dynamics analyses supported stable protein–ligand complexes, but biochemical, cellular, and clinical validation remain necessary before these candidates can be considered antiviral inhibitors.
-
Ferrostatin-1: From Ferroptosis Rescue to Translation
2026-08-14
Ferrostatin-1 (Fer-1) is more than a ferroptosis inhibitor: it is a causal probe for iron-dependent oxidative injury. This article translates recent plant-pathogen findings into a rigorous strategy for ferroptosis assays, cancer biology research, neurodegenerative disease models, and broader translational programs.
-
From RB1 Cell States to Hec1-Targeted Translation
2026-08-13
TAI-1 provides a potent Hec1-directed perturbation strategy for studying mitotic vulnerability, while RB1-deficient retinal organoids offer a cell-state-resolved framework for testing when genotype becomes therapeutic opportunity. Together, these insights support a more rigorous path from cancer mechanism to translational assay design.
-
CNS Myelin Damage Can Remodel Before Loss
2026-08-13
Arafa and colleagues show that early CNS myelin injury is characterized by swelling that can resolve rather than inevitably progressing to sheath loss. By combining longitudinal imaging across zebrafish, rodents, and human tissue with activity manipulation, the study identifies neuronal activity as a modifiable risk factor and positions early myelin remodeling as a potential therapeutic window.
-
TEAD, Ferroptosis, and HCC: Insights from Ren et al.
2026-08-12
Ren et al. combined public-database analyses with in vitro experiments to identify TEAD2 as a prognostic factor and regulator of ferroptotic vulnerability in hepatocellular carcinoma. The study connects TEAD2 expression with adverse clinical outcomes, iron accumulation, oxidative injury, and immune-cell infiltration, while also defining useful boundaries for translating bioinformatic associations into mechanistic research.